The objective of treatment with potassium citrate extended-release tablets is to provide potassium citrate in sufficient dosage to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0...
戊戌数据药品标准数据库提供了Potassium Citrate Extended-Release Tablets枸橼酸钾缓释片美国药典标准的查询检索,包括Potassium Citrate Extended-Release Tablets枸橼酸钾缓释片美国药典的版本USP35-NF30页码,以及药典的查询与下载.
»Potassium Citrate Extended-Release Tablets contain not less than 90.0percent and not more than 110.0percent of the labeled amount of C6H5K3O7.Packaging and storage— Preserve in tight containers. Identification— A: Powder 5Tablets,mix with 20mLof water,and filter:the filtrate responds to...
枸橼酸钾缓释片药品报告提供了枸橼酸钾缓释片的各种信息,包括枸橼酸钾缓释片的药品简介,新药研发进度,仿制药申报进度,中国药品注册情况,一致性评价进度,药品临床试验进度,药品上市等信息.更多药物报告的查询就在戊戌数据药物报告数据库.
The high dose extended-release potassium citrate tablet of this invention has robust batch-to-batch dissolution and friability; and leads to improved production capacity and reduced production cost.Mendoza Wendell G.Santos Rita Josefina M.Dee Kennie U....
Potassium citrate extended-release tablets are contraindicated: • In patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. Such conditions include: chronic renal failure, uncontrolled diabetes ...
3 药品名称 POTASSIUM CITRATE 申请号 077440 产品号 001 活性成分 POTASSIUM CITRATE 市场状态 处方药 剂型或给药途径 TABLET, EXTENDED RELEASE;ORAL 规格 5MEQ 治疗等效代码 AB 参比药物 否 批准日期 2006/06/09 申请机构 COREPHARMA LLC 4 药品名称 POTASSIUM CITRATE 申请号 077440 产品号 002 活性成分 POTAS...
Citrate can be given as a liquid (e.g.,Bicitra, Polycitra, or Polycitra‐K, Alza Pharmaceuticals) or as an extended‐release tablet (10mEq, Urocit‐K, Mission Pharmacal). ▪ Bicitra provides 1 mEq/ml of sodium and potential alkali. ...
K-TAB (potassium chloride extended-release tablets) is a solid oral dosage form of potassium chloride containing 750 mg of potassium chloride, USP, equivalent to 10 mEq of potassium in a film-coated (not enteric-coated), wax matrix tablet. This formulation is intended to slow the release of...
Slow-K, potassium chloride extended-release tablets USP, is a sugar-coated (not enteric-coated) tablet for oral administration, containing 600 mg of potassium chloride (equivalent to 8 mEq) in a wax matrix. This formulation is intended to provide an extended-release of potassium from the matrix...